Mochida Pharma 持田製薬 only recently re-joins the net profit club!

 

A purchase this year at ¥3,150 only popped back into the plus column 5 trading days prior after an absence of 4 months subsequent to the ¥40 dividend going ex- on 28/3/24. A long-term uptrend line was briefly broken in mid-June and  it looks to be completing a breakout from a large pennant-type bullish formation going back to its 21st century peak of ¥6,110 in 2019. Its adjusted zenith price is even higher at almost ¥22,800 in 1984 {de facto price of ¥16,600}, which was when it was rumoured to have discovered a cure for cancer. It has fulfilled its annual TD downtrend-count of nine from that long ago summit down to the  ¥1,025 low in '98, making that, in all likelihood, the ultimate low unless the above uptrend line is broken decisively.

Dividends to be received(11/7) : Tobishima, Shindengen, Mochida, Shikibo, Futaba, Tsutsumi, Nippon Felt, Kuroda Precision, Ogura Clutch, Carchs, Fujix, Nichiwa & FujiSash